Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
France's debt climbs to highest since 1978: ministry
-
Cuba works to restore power after another blackout
-
Thousands protest inaction over climate crisis in Switzerland
-
Brigitte Bardot widower slams sale of star's belongings
-
UK actor Naomi Watts honoured at Spain film festival
-
Indonesia accepts Malaysia's help to tackle wildfires
-
Trump signs bill authorizing sweeping Russia sanctions
-
Nvidia, OpenAI CEOs to attend Xi dinner at White House
-
Anthropic picks Accenture for in-house AI safety evaluation
-
Cuba hit with seventh major blackout of the year
-
Hushing and hedging: US companies retreat on climate
-
Nigeria miners struggled to breathe in cell before 37 died: survivors
-
Crisis-wracked Volkswagen warns of 10-bn-euro hit to profits
-
Warren Buffett steps down as Berkshire Hathaway chairman
-
Shakira to cap off world tour with Madrid 12-gig run
-
Isolated Syrian-Druze city blames Damascus for shortages
-
Isolated Syrian-Druze city shortages
-
Kerry James Marshall: American 'blackness' painter celebrated in Europe
-
UNESCO can be 'moderator' in AI debate: chief to AFP
-
Infantino 'must go', says German FA vice-president
-
Russia seizes assets of Nestle, French firms
-
Japan's busiest rail station tests robot bins
-
Anthropic says AI systems moving towards building themselves
-
Backpackers fret over Australian visa crackdown
-
Asian stocks boosted by falling oil, yen weakens after BoJ rate hike
-
Bank of Japan hikes rates to 31-year high to battle inflation
-
Afghan medical students in Pakistan hope court stops college expulsions
-
AI doomsday warnings unlikely to slow IPOs but questions linger
-
Australia to detain tourists who overstay visa, minister says
-
In Brazil's Amazon, the hunt for oil fuels hopes and fears
-
Asian stocks track Wall St rally as oil prices drop
-
Baby orangutans in India expose 'frightening' scale of trafficking
-
Prized Mexican relic returns on loan, two centuries on
-
Oversight Board blasts 'inadequate' Meta safeguards for AI deepfakes
-
'In our lane': Fed's Warsh defies Trump but still fighting for credibility
-
Harry makes first public appearance since return to UK
-
Trump admin makes major cut to endangered species protections
-
Princess Diana's brother makes new explosive claims against Charles
-
GM delivers first components for US interceptor missiles
-
Trump admin overhauls key protection for endangered species
-
Travis Scott and Keith Richards feature on GTA VI soundtrack
-
Mbappe draws political fire over Ceuta t-shirt controversy
-
King Charles warns tech bosses of 'existential dangers' of AI
-
Third malaria death in Germany from outbreak tied to Frankfurt airport
-
French fishermen block ports over petrol prices
-
AtlasClear Holdings Reports Preliminary Fiscal 2026 Revenue of Approximately $20.1 Million, Up 85%; Revenue Plus Interest Income of Approximately $21.9 Million
-
Micron's Taiwan workers say 68 months' bonus not enough
-
'Another arrow to the quiver': World Bank posts record private capital mobilization
-
Canada's Carney pushes 'new alliance' with EU despite Trump threats
-
Ireland to boycott Eurovision 2027 over Gaza
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
H.Meyer--CPN